Noopept 10mg №50 pills
Release form, composition and packaging◊ White pills, round, flat-cylindrical, with a chamfer.
Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) 10 mg
Excipients: starch potato 13.5 mg, lactose monohydrate 55 mg, microcrystalline cellulose 21.2 mg, magnesium stearate 0.3 mg, povidone 0.0008 mg.
25 pcs. - Contour cell packages (2) - cardboard packs.
pharmachologic effectNoopept has nootropic and neuroprotective properties. Improves learning ability and memory, acting on all phases of processing: initial information processing, consolidation, extraction. Interferes with the development of amnesia caused by electric shock, blockade of central cholinergic structures, glutamatergic receptor systems, deprivation of the paradoxical phase of sleep. The neuroprotective (protective) action of Noopept manifests itself in increasing the resistance of brain tissue to damaging effects (trauma, hypoxia, electroconvulsive, toxic) and reducing the degree of damage to brain neurons. The drug reduces the focus on the thrombotic stroke model and prevents neuronal death in the tissue culture of the cerebral cortex and cerebellum exposed to neurotoxic concentrations of glutamate, free-radical oxygen. Noopept has an antioxidant effect, blocks the potential-dependent calcium channels of neurons, weakens the neurotoxic effect of excess calcium, improves the rheological properties of blood, and has antiaggregant, fibrinolytic, anticoagulant properties.
The nootropic effect of the drug is associated with the formation of cycloprolylglycine, which is similar in structure to an endogenous cyclic dipeptide with antiamnesic activity, as well as with the presence of a cholinopositive effect.
Noopept increases the amplitude of the transcallosal response, facilitating the associative connections between the hemispheres of the brain at the level of cortical structures. Contributes to the restoration of memory and other cognitive functions impaired as a result of damaging effects - brain injury, local and global ischemia, prenatal damage (alcohol, hypoxia).
The therapeutic effect of the drug in patients with organic disorders of the central nervous system appears from 5-7 days of treatment. Initially, the anxiolytic and light stimulating effects that are present in the activity spectrum of Noopept&№174; are realized, which manifest themselves in the reduction or disappearance of anxiety, increased irritability, affective lability, and sleep disorders. After 14-20 days of therapy, a positive effect of the drug on cognitive functions, parameters of attention and memory is revealed.
Noopept has a vegetative-normalizing effect, helps reduce headaches, orthostatic disorders, tachycardia. With the abolition of the drug is not observed "withdrawal" syndrome.
It has no damaging effect on the internal organs; does not lead to changes in the cellular composition of blood and biochemical parameters of blood and urine; does not possess immunotoxic, teratogenic effect, does not show mutagenic properties.
PharmacokineticsN-phenylacetyl-L-prolylglycine ethyl ester, being absorbed in the gastrointestinal tract, enters the systemic circulation in an unchanged form, penetrates through the blood-brain barrier, is detected in the brain in higher concentrations than in the blood. The time to reach the maximum concentration on average is 15 minutes. T1 / 2 from plasma - 0.38 hours. Partially stored unchanged, partially metabolized to form phenylacetic acid, phenylacetylproline and cycloprolylglycine. It has a high relative bioavailability (99.7%), does not accumulate in the body, does not cause drug dependence.
DosageNoopept is applied inside, after eating. Treatment begins with a dose of 20 mg, divided into two doses of 10 mg during the day (morning and afternoon). With insufficient efficacy of therapy and with good tolerability of the drug, the dose is increased to 30 mg (see “Special Instructions”), distributing it into three doses of 10 mg per day. Do not take the drug later than 18 hours. The duration of the course of treatment is 1.5-3 months. Repeated treatment if necessary can be carried out after 1 month.
OverdoseSpecific manifestations of overdose is not installed.
Drug interactionThe interaction of Noopept with alcohol, hypnotic drugs and antihypertensive drugs and psychostimulant drugs has not been established.
Pregnancy and lactationContraindicated during pregnancy and lactation.
Side effectsAllergic reactions are possible. In patients with arterial hypertension, mostly severe, a rise in blood pressure may be observed while taking the drug.
Terms and conditions of storageIn a dry, dark place, at a temperature not higher than 25 ° C. Keep out of reach of children. Shelf life - 3 years.
IndicationsImpaired memory, attention, other cognitive functions and emotional labile disorders (including in elderly patients) with:
- effects of traumatic brain injury;
- postkommotsionnom syndrome;
- cerebral vascular insufficiency (encephalopathies of various origins);
- asthenic disorders;
- other conditions with signs of reduced intellectual productivity.
- lactation period;
- age up to 18 years;
- hypersensitivity to the drug;
- Lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
- pronounced disorders of the liver and kidneys.
special instructionsIf you need to increase the dose of the drug (up to 30 mt / day), with prolonged use, as well as with simultaneous use with other drugs, the appearance of adverse reactions or deterioration of the condition should consult a doctor.
Influence on ability to drive machinery and vehicles.Noopept does not affect the ability to drive machinery and vehicles.
When kidney damageContraindicated in severe renal impairment.
With abnormal liver functionContraindicated in marked disorders of the liver.
Use in childhoodContraindicated in children under 18 years.
Pharmacy sales termsOver the counter.
It is a pharmaceutical drug. Use only as directed by your doctor.